Disclosures for "Efficacy of Omaveloxolone in Friedreich’s Ataxia: Post-Hoc Analysis Using Global Statistics Test to Strengthen Secondary Endpoint Analyses")
-
Dr. Hendrix has received personal compensation for serving as an employee of Pentara Corporation. Dr. Hendrix has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pentara Corporation. Dr. Hendrix has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pentara Corporation. The institution of Dr. Hendrix has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pentara Corporation. Dr. Hendrix has stock in Pentara. Dr. Hendrix has received publishing royalties from a publication relating to health care.
-
Angie Goldsberry has nothing to disclose.
-
Colin Meyer has nothing to disclose.
-
The institution of Dr. Lynch has received research support from reata. The institution of Dr. Lynch has received research support from PTC.